MedPath

Effect of finastride on TUR-P blood loss

Not Applicable
Conditions
BPH.
Hyperplasia of prostate
Registration Number
IRCT2015050922168N1
Lead Sponsor
Ahvaz Jundishapur University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Male
Target Recruitment
60
Inclusion Criteria

BPH patients who are candidate for TUR-P due to obstructive urinary symptoms

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Hematocrit. Timepoint: Just before the surgery and 6 hours after. Method of measurement: %.;Tissue microvascular density. Timepoint: After TURP. Method of measurement: The average number of vessels counted in 10 non-overlapping hpf.;Tissue Vascular endothelial growth factor. Timepoint: After TURP. Method of measurement: The average tissue expression of VEGF in specimens.;Surgens satisfaction. Timepoint: After TURP. Method of measurement: based on visual analog scale- 0 to 10.;Removed tissue weight. Timepoint: After TURP. Method of measurement: weight of removed tissue by TURP in gram.;Percent of tissue removed by TURP. Timepoint: After TURP. Method of measurement: weight of tissue removed by TURP devided by total prostate weight.;Total operative time. Timepoint: after TURP. Method of measurement: time from starting TURP until foley fixation- in minutes.
Secondary Outcome Measures
NameTimeMethod
Short term complications. Timepoint: one week after TURP. Method of measurement: complications that will happen within a week after the surgery.;Long term complications. Timepoint: After one week following TURP. Method of measurement: complications that happens after a week within 3 months after TURP.
© Copyright 2025. All Rights Reserved by MedPath